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Alzheimer's diseaseThe present study had focused on the behavioral phenotype and gene expression proﬁle of molecules related to
insulin receptor signaling in the hippocampus of 3 and 6 month-old APPswe/PS1dE9 (APP/PS1) transgenic
mouse model of Alzheimer's disease (AD). Elevated levels of the insoluble Aβ (1–42) were detected in the
brain extracts of the transgenic animals as early as 3 months of age, prior to the Aβ plaque formation (pre-plaque
stage). By the early plaque stage (6 months) both the soluble and insoluble Aβ (1–40) and Aβ (1–42) peptides
were detectable. We studied the expression of genes related to memory function (Arc, Fos), insulin signaling,
including insulin receptor (Insr), Irs1 and Irs2, as well as genes involved in insulin growth factor pathways,
such as Igf1, Igf2, Igfr and Igfbp2. We also examined the expression and protein levels of key molecules related
to energy metabolism (PGC1-α, and AMPK) and mitochondrial functionality (OXPHOS, TFAM, NRF1 and
NRF2). 6 month-old APP/PS1mice demonstrated impaired cognitive ability, were glucose intolerant and showed
a signiﬁcant reduction in hippocampal Insr and Irs2 transcripts. Further observations also suggest alterations in
key cellular energy sensors that regulate the activities of a number of metabolic enzymes through phosphoryla-
tion, such as a decrease in the Prkaa2 mRNA levels and in the pAMPK (Thr172)/Total APMK ratio. Moreover,
mRNA and protein analysis reveals a signiﬁcant downregulation of genes essential for mitochondrial replication
and respiratory function, including PGC-1α in hippocampal extracts of APP/PS1mice, compared to age-matched
wild-type controls at 3 and 6 months of age. Overall, the ﬁndings of this study show early alterations in genes in-
volved in insulin and energy metabolism pathways in an APP/PS1 model of AD. These changes affect the activity
of keymolecules likeNRF1 and PGC-1α, which are involved inmitochondrial biogenesis. Our results reinforce the
hypothesis that the impairments in both insulin signaling and energy metabolism precede the development of
AD amyloidogenesis.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer's disease (AD) is themost common cause of senile demen-
tia and the incidence rates of the disease are increasing exponentially duei Farmacognosia, Facultat de
3, E-08028 Barcelona, Spain.to the amount of aged population. AD diagnosis is based on the detection
of senile amyloid-β (Aβ) plaques and neuroﬁbrillary tangles in the brain
[1]. Although the exact mechanisms triggering neurodegeneration in
AD remain unclear, a number of hypotheses have been proposed [2–11].
In recent years, several studies have focused on the potential rela-
tionship between AD and metabolic disorders [14–17]. Obesity and
diabetes signiﬁcantly increase the risks of cognitive decline andAD, sug-
gesting that brain glucose metabolism impairments [18–25] may be
linked toADpathogenesis [14]. Both theAD and type 2 diabetesmellitus
(T2DM) are associated with peripheral and central insulin signaling
abnormalities, including alterations in brain insulin and insulin-like
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naling pathways affect neuronal survival, energy homeostasis, gene
expression and memory processes [23–30]. For instance, insulin
and IGF1 regulate the expression and phosphorylation of Tau protein
through activation of kinases [26–36].
Therefore, AD could be considered as a “type 3 diabetes”metabolic
disorder, with insulin providing the link connecting both chronic dis-
eases [19–22]. Several studies have reported a role for insulin in the con-
trol of neuronal function in cortical and hippocampal areas, which are
involved in memory processing and cognitive functions [24–26]. Thus,
insulin directly inﬂuences neurons, modulates neurotransmitter re-
lease, neuronal outgrowth, neuronal survival, aswell as synaptic plastic-
ity [19]. Moreover, it has been demonstrated that soluble Aβ oligomers
alter insulin signaling because they bind to insulin receptors in hippo-
campal neurons, thereby inducing receptor mobilization from the
membrane and into the cell [15].
Another molecule implicated both in diabetes and AD is the insulin-
degrading enzyme (IDE). IDE is capable of degrading both insulin and
Aβ, however it binds insulin with a much higher afﬁnity. In an animal
model of T2DM, elevated levels of circulating insulin resulted in compet-
itive inhibition of IDE, thus causing an increase in Aβ levels. Additionally,
mice lacking IDE have lower rates of Aβ and insulin degradation, and
develop hyperinsulinemia and Aβ deposits in the brain [19–21].
AD etiology is complex andAβ by itself is unable to account for all as-
pects of AD [1–6,37–41]. In order to identify the underlying causes of the
disease, it is of utmost importance to understand the potential correla-
tions between Aβ oligomers and hippocampal metabolism in early
disease-stages, prior to plaque deposition. Most of AD research is cur-
rently undertaken in animal models that have increased Aβ levels com-
pared to controls, andwhile Aβ pathology is mimicked in these models,
many other factors associated with AD are not. Transgenic mice that
carry an APP and presenilin 1 (PS1) mutations show AD-like pathology
and memory impairment, and are useful for studying AD and testing
possible treatments [42]. The current study, carried out in an APP/PS1
model of AD, aimed to identify the metabolic pathways responsible for
the onset of AD, with the main focus on the early disease-stages, prior
to the formation of senile plaques and memory loss. For this purpose,
we examined behavioral phenotype and mRNA expression and protein
levels of genes related to insulin receptor andmitochondria signaling in
3 and 6 month-old APP/PS1 mice. Three month-old animals were cho-
sen because at this age, neither signiﬁcant cognitive loss, nor brain Aβ
plaques are detectable compared to the six month-old mice, which ex-
hibit high brain Aβ content and memory loss [12–14].
2. Materials and methods
2.1. Animals
Male APPswe/PS1dE9 and C57BL/6 mice were used in this study.
APP/PS1 animals co-express a Swedish (K594M/N595L) mutation of a
chimeric mouse/human APP (Mo/HuAPP695swe), together with the
human exon-9-deleted variant of PS1 (PS1-dE9), allowing these mice
to secrete elevated amounts of human Aβ peptide. Both mutations are
associatedwithAD, are under control of themouse prion protein promot-
er, directing both mutated proteins mainly to the CNS neurons, and
result in age-dependent amyloid plaque depositions in mouse brain.
The APPswe-mutated APP is a favorable substrate for β-secretase, where-
as the PS1dE9 mutation alters β-secretase cleavage, thereby promoting
overproductionofAβ42. The animalswere kept under controlled temper-
ature, humidity and light conditions with food and water provided ad
libitum. Mice were treated in accordance with the European Community
Council Directive 86/609/EEC and the procedures established by the
Department d'Agricultura, Ramaderia i Pesca of the Generalitat de
Catalunya. Every effort was made to minimize animal suffering and to
reduce the number of animals used. Fifty animals, divided into four
groups, were used for the present study, with at least 10 wild-typeand 10 APP/PS1 transgenic mice of 3 and 6 months of age, per group.
Following in vivo testing, the animals were sacriﬁced and at least 6
mice in each group were used for RNA and protein extract isolation,
with an additional 4 mice for immunohistochemistry.
2.2. Glucose and insulin tolerance tests
Intraperitoneal glucose tolerance tests (IP-GTT) and insulin tolerance
tests (ITT) were performed in accordance with the previously published
guidelines [72]. For IP-GTT, mice were fasted overnight for 16 h. The
test was performed in a quiet room, preheated to +30 °C. The tip of the
tail was cut with the heparin-soaked (Heparina Rovi, 5000 IU/ml; Rovi
S.A.; Madrid, Spain) scissors, 30 min prior to 1 g/kg intraperitoneal glu-
cose injection (diluted in H2O). Blood glucose levels of the tail vein
were measured at−30, 0, 5, 15, 30, 60 and 120 min after the glucose in-
jection with the Ascensia ELITE blood glucose meter (Bayer Diagnostics
Europe Ltd.; Dublin, Ireland). ITT was performed in similar conditions
with the 0.25 IU/kg of human insulin, diluted in saline (Humulina Regu-
lar, 100 IU/ml/Lilly, S.A.; Madrid, Spain), except that themice underwent
a 5-hourmorning fast. Blood glucose levels weremeasured at−30, 0, 15,
30, 45 and 60 min after the insulin administration. If, during this time,
blood glucose levels dropped to below 20 mg/dl, 1 g/kg glucose was ad-
ministered to counteract the effects of insulin, in order to reduce animal
suffering.
2.3. Novel object recognition test
The test was conducted as described previously [43] in a 90° two
arm, 25 cm long, and 20 cmhighmaze. The light intensity in themiddle
of the ﬁeld was 30 lx. The objects to be discriminated were plastic ﬁg-
ures (object A: 5.25 cm high, object B: 4.75 cm high). First, mice were
individually habituated to the apparatus for 10 min a day, for two
days. On the third day, they were submitted to a 10 min acquisition
trial (ﬁrst trial) during which they were placed in themaze in the pres-
ence of two identical novel objects (A+A, or B+B) placed at the end of
each arm. A 10 min retention trial, with the objects (A + B) (second
trial) occurred 2 h later. The amount of exploration time each animal
spent on objects A and B during the acquisition trial varied between 5
and 20 s, depending on the individual mouse. Total exploration time be-
tween the 2 objects when calculated for each individual animal indicat-
ed the absence of the object preference bias (Fig. 1C) (n = 5–9 per
group). During the retention trial, the times that the animal took to
explore the new object (tn) and the old object (to) were recorded.
A discrimination index (DI) was deﬁned as (tn− to) / (tn + to). In
order to avoid further object preference biases, objects A and B
were counterbalanced so that half of the animals in each experimental
group were ﬁrst exposed to object A and then to object B, whereas the
other half saw ﬁrst object B and then object A. The maze, the surface,
and the objects were cleaned with 96° ethanol between animals, so as
to eliminate olfactory cues.
2.4. Immunohistochemistry
For detection of Aβ deposits, free-ﬂoating coronal sections, 20 μm
thick, were rinsed with 0.1 mol/l PB, pH 7.2, and pre-incubated in 88%
formic acid. Then, sections were treated with 5 ml/l H2O2 and 100 ml/l
methanol in PBS and pre-incubated in a blocking solution (100 ml/l of
FBS, 2.5 g/l of BSA and 0.2 mol/l of glycine in PBS with 5 ml/l of Triton
X-100). After that, sections were incubated overnight (O/N) at 4 °C
with the primary mouse anti-human beta-amyloid clone 6F/3D anti-
body (1:100; DakoCytomation, Denmark). Then, sectionswere incubat-
ed with the biotinylated secondary antibody (1:200; Sigma-Aldrich)
followed by the avidin–biotin–peroxidase complex (ABC; 1:200; Vector,
Burlingame, CA). Peroxidase reactionwas developedwith 0.5 g/l diami-
nobenzidine in 0.1 mol/l PB and 0.1 ml/l H2O2, and immunoreacted
Fig. 1.Representative immunohistochemical stainingwith theAβ-speciﬁc 6F/3D antibody, in 3 and 6 month-oldmice, demonstrating Aβ plaque deposits in the hippocampus of 6 month-
old APP/PS1 animals (A). mRNA expression proﬁle of app, fos and Arc in the hippocampal extracts (n = 6) (B). The results of the 2 object novel object recognition test, demonstrating an
absence of the object preference bias and a signiﬁcant memory loss in 6 month-old APP/PS1 animals, compared to wild-type controls (n = 7–12) (C). Concentrations of the soluble and
insoluble human Aβ (1–40) and Aβ (1–42) peptides in the cortical extracts in 3 and 6 month-old APP/PS1 mice, expressed as pg/mg of total protein as determined by ELISA (n = 5–6)
(D). (Statistical analysis was performed with one-way ANOVA, with Tukey's post-hoc test, where * denotes p b 0.05, ** denotes p b 0.01, and *** denotes p b 0.001.)
Table 1
A list of antibodies used for the immunoblotting experiments.
Protein Antibody
pAMPK (Thr 172) #2531 (Cell signaling)
AMPK #2532 (Cell signaling)
PGC1A 101707 (Cayman chemical)
TFAM DR1071b (Calbiochem)
NRF1 Sc-28379 (Santa Cruz biotech)
IDE Ab32216 (Abcam)
pGSK3B (Tyr 216) Ab74754 (Abcam)
pGSK3B (Ser 9) #9336 (Cell signaling)
GSK3B #9315 (Cell signaling)
pCDK5 (Tyr 15) ab63550 (Abcam)
CDK5 Sc-173 (Santa Cruz biotech)
P35 #2680 (Cell signaling)
pTAU (Ser 199) 44734G (Life Technologies)
pTAU (Thr 205) 44738G (Life Technologies)
pTAU (Ser 396) 44752G (Life Technologies)






2nd–ary Anti-Mouse 170-5047 (Biorad)
2nd–ary Anti-Rabbit NA934V (GE Healthcare)
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examined under a light microscope (Olympus BX61).
2.5. Western blot analysis
Aliquots of hippocampus homogenate containing 15 mg of protein
per samplewere analyzed using theWestern blotmethod. In brief, sam-
ples were placed in a sample buffer (0.5 m Tris–HCl, pH 6.8, 10% glycer-
ol, 2% (w/v) SDS, 5% (v/v) 2-mercaptoethanol, 0.05%bromophenol blue)
and denatured by boiling at 95–100 °C for 5min. Sampleswere separat-
ed by electrophoresis on 10–15% acrylamide gels. Following this, the
proteins were transferred to PVDF sheets using transblot apparatus.
Membranes were blocked overnight with 5% non-fat milk dissolved in
TBS-T buffer (50 mM Tris; 1.5% NaCl, 0.05% Tween 20, pH 7.5). They
were then incubated with primary antibodies, as detailed in Table 1.
After O/N incubation, blots were washed thoroughly in TBS-T buffer
and incubated for 1 h with a peroxidase-conjugated IgG secondary
antibody (1:2000). Immunoreactive protein was detected using a
chemiluminescence-based detection kit. Protein levels were deter-
mined by densitometry, using Chemi doc XRS + Molecular Imager de-
tection system (Bio-Rad), with ImageLab image analysis software.
Measurements are expressed as arbitrary units. All results are normal-
ized to GAPDH, unless stated otherwise.
2.6. Serum insulin ELISA
Heart puncture was used to collect whole blood samples from 3 and
6 month-old wild-type and APP/PS1 mice, following a 5-hour morning
fast, at the point of sacriﬁce. Blood samples were transferred to
Serum-Gel Z microcentrifuge tubes (Sarstedt, Numbrecht, Germany),for serum separation. The samples were collected and kept at room tem-
perature, and the serum was separated by centrifugation for 10 min at
5000 ×g. Serum insulin levels were measured with Rat/Mouse Insulin
ELISA kit (Cat #: EZRMI-13K; EMD Millipore; St. Charles, MO, USA),
according to manufacturer's instructions, utilizing 10 μl of mouse serum.
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Aβ 1–40 and Aβ 1–42 were measured in cortical extracts according
to a previously published procedure [44]. In brief, the samples were
weighed and homogenized in a 8× volume of PBS with AEBSF protease
inhibitor cocktail set (Cat # 539131; Calbiochem; La Jolla, CA, USA). The
soluble fractionwas separated by centrifuging the samples for 10min at
4000 ×g. The pellets containing insoluble Aβ peptides were solubilized
in a 5 M guanidine HCl/50 mM Tris HCl solution by incubating for 3.5
h on an orbital shaker at room temperature in order to obtain insoluble
fraction. The levels of soluble and insoluble Aβ 1–40 and Aβ 1–42 were
determined employing the commercially available human ELISA kits
(Cat # KHB3481 and KHB3441; Invitrogen, Camarillo, CA, USA). Data
obtained from the cortical homogenates are expressed as picograms of
Aβ content per milligrams of total protein (pg/mg).
2.8. RNA extraction and quantiﬁcation
Total RNA was isolated from the hippocampi of wild-type and APP/
PS1 transgenic mice, as described previously [73]. Brieﬂy, the tissue
was homogenized in the presence of Trizol reagent (Life Technologies
Corporation). Chloroform was added and the RNA was precipitated
from the aqueous phase with isopropanol at 4 °C. RNA pellet was
reconstituted in RNAse-free water, with the RNA integrity determined
by Agilent 2100 Bioanalyzer.
2.9. Quantitative RT-PCR
First-strand cDNA was reverse transcribed from 2 μg of total RNA
from the hippocampi of 3 and 6 month-oldmice, using the High Capac-
ity cDNA Reverse Transcription kit, according to manufacturer's proto-
col (Applied Biosystems). Equal amounts of cDNA of each individual
animal were subsequently used for qRT-PCR, and each sample was
analyzed in triplicate for each gene. TaqMan gene expression assays
(Applied Biosystems) as detailed in Table 2 were used to determine
transcription levels of individual genes. qRT-PCR was performed on
the StepOnePlus Real Time PCR system (Applied Biosystems) and nor-
malized to the average transcription levels of gapdh and tbp, using the
delta–delta Ct method.
2.10. Statistical analysis
All data are presented as means ± SEM, and differences are consid-
ered signiﬁcant at p b 0.05, p b 0.01 and p b 0.001. Differences betweenTable 2




















tfam Mm00447485_m1samples/animals were evaluated using either one-way ANOVA, with
Tukey's post-hoc test, where * denotes p b 0.05, ** denotes p b 0.01,
and *** denotes p b 0.001 andwith the student's t-test, where $ denotes
p b 0.05, $$ denotes p b 0.01 and $$$ denotes p b 0.001. Both the statis-
tical analyses and the graphs presented here were created with the
GraphPad InStat software V5.0 (GraphPad Sofware Inc., San Diego, CA,
USA).
3. Results
3.1. Early phenotypical signs of amyloidogenesis in APP/PS1 mice
In order to determine the extent of the amyloid deposition in the
brains of APP/PS1 mice, hippocampal sections were stained with the
6F/3D monoclonal antibody, which is speciﬁc for the human form of
the Aβ peptide. It was previously reported that the amyloid plaque de-
posits ﬁrst start to appear at the age of 6 months in this model [13,14].
In agreementwith the earlier studies, our immunohistochemical results
demonstrated neither diffuse nor ﬁbrillar plaque deposition in the
brains of APP/PS1 mice at 3 months of age. In contrast, Aβ protein ag-
gregates were clearly visible by the age of 6 months (Fig. 1A). In addi-
tion, a signiﬁcant increase in the mRNA levels of the app (utilizing a
probe which recognizes both human and mouse transcripts) was de-
tected in hippocampal extracts of both3 and6 month-old animals. Like-
wise, we observed a signiﬁcant reduction in themRNA levels of Arc and
fos, which play a role in memory function, in the brains of APP/PS1mice
[45] (Fig. 1B). Moreover, we have characterized the progression of
cognitive impairment, utilizing a 2 object novel object recognition test.
Our results showed a signiﬁcant memory loss in 6 month-old APP/PS1
mice (Fig. 1C).
Interestingly, we have detected signiﬁcant levels of the insoluble Aβ
(1–42) peptides in the cortical homogenates of 3 month old APP/PS1
mice (N1000 pg/mg), at an age when Aβ plagues are not yet detectable
by immunohistochemistry. The amyloid burden was further increased
in 6 month old transgenic animals, with the detectable levels of both
soluble and insoluble Aβ (1–40) (N140 and N 680 pg/mg) and of soluble
and insoluble Aβ (1–42) (N150 and N2300 pg/mg) (Fig. 1D).
3.2. Glucose and insulin tolerance tests and peripheral insulin levels
Since a connection between AD and T2DM has been established
during the past decade, we intended to identify anymetabolic perturba-
tions in glucosemetabolism in the APPswe/PS1dE9 strain [18]. In fact, as
shown in Fig. 2, APP/PS1 mice exhibited impaired fasting glucose and
insulin tolerance, following IP-GTT and ITT, respectively. Interestingly,
the biggest differences in blood glucose levels, between the wild-type
and transgenic animals, were detected from 30 to 120 min following
i.p. glucose administration in IP-GTT or insulin administration in ITT.
In addition, a slight increase in fasting peripheral insulin levels, deter-
mined by ELISA, was observed in 6 month-old APP/PS1mice, compared
to age-matched controls. Having conﬁrmed the existence of the periph-
eral metabolic phenotype in the APP/PS1 mice, we then proceeded to
study the expression of genes related to insulin metabolism in the
brain, with a particular focus on hippocampal insulin receptor signaling
pathway.
3.3. Identiﬁcation of differentially expressed genes related to insulin
receptor
Previous studies demonstrated alterations in brain insulin signaling in
AD, but the onset and the severity of this impairment are unclear [43–46].
For this reason, we evaluatedmRNA expression of preproinsulin 1 (Ins1),
insulin receptor (Insr), insulin receptor substrates 1 (Irs1) and 2 (Irs2),
insulin-like growth factors I (Igf1) and II (Igf2), IGF receptor (Igfr), as
well as insulin-like growth factor-binding protein 2 (igfbp2), at 3 and
6 months of age (Fig. 3). We detected a small, but signiﬁcant reduction
Fig. 2. Fasting serum insulin levels ELISA (n=5–7) (A), insulin tolerance test (n= 5–7) (B) and intraperitoneal glucose tolerance test (n= 5–12) (C) in 3 and 6 month-oldwild-type and
APP/PS1mice. For the ITT and the IP-GTT, AUC datawere calculated from the timepoint 0 till the end of the experiment (Statistical analysiswas performedwith the student's t-test, where $
denotes p b 0.05.)
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APP/PS1 mice, compared to age-matched controls. Interestingly, the
expression of both Igf2 and Igfbp2 transcripts was signiﬁcantly increased
at 6 months in transgenic animals.Fig. 3.mRNAexpression proﬁle of genes related to insulin signaling pathway in thehippocampa
was performed with one-way ANOVA and with Tukey's post-hoc test, where * denotes p b 0.03.4. Energymetabolism is impaired in the early stages of the amyloidogenesis
AMP-activated protein kinase (AMPK) is a sensor of cellular stress
that maintains energy homeostasis by promoting mitochondriall extracts of 3 and 6 month-oldwild-type andAPP/PS1mice (n= 4–6). (Statistical analysis
5.)
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activated receptor-γ coactivator 1α (PGC-1α) signaling pathway
[47–54]. We detected a signiﬁcant reduction in the mRNA levels of the
alpha 2 (Prkaa2), but not of the alpha 1 (Prkaa1) isoform of the catalytic
subunit of AMPK, in the hippocampi of 3 month-old APP/PS1 mice,
compared to wild-type controls (Fig. 4A). This observation is consistent
with the slight reduction in the protein levels of phosphorylated AMPK
(pAMPK (Thr172)/Total APMK ratio) (Fig. 4B). Thus, our data suggest
alterations in a key cellular energy sensor that regulates the activities
of a number of molecules involved in cellular metabolism.
PGC-1α is involved in energy homeostasis and glucose metabolism,
as well as in mitochondrial metabolism and biogenesis [49,50]. In the
current study, we detected a signiﬁcant reduction in PGC-1α mRNA
and protein (Fig. 4) levels in the hippocampi of 3 and 6 month-old
APP/PS1 mice, compared to control animals. Since PGC-1α regulates
the transcriptional activity of genes essential for mitochondrial replica-
tion and respiratory function, such as estrogen-related receptorα (ERR-
α), nuclear respiratory factor (NRF) and mitochondrial transcription
factor A (TFAM), we proceeded to study their mRNA and protein levels.
3.5. The impairment of mitochondrial biogenesis is involved in the early
stages of the amyloidogenesis
It has been hypothesized that mitochondrial dysfunction could be
a trigger of AD [49–54]. In fact, mRNA expression analysis of genes,
downstream to PGC-1α, conﬁrmed signiﬁcant reductions in Nrf1
and Nrf2 transcripts in the hippocampi of 3-month old APP/PS1 ani-
mals, compared to controls. mRNA levels of Tfam were also slightly
reduced at this age, although the observed changes did not reach
statistical signiﬁcance (Fig. 4A). These data suggest that reduced
mitochondrial biogenesis is an early event in the hippocampus of
APP/PS1 mice.Fig. 4.mRNA expression proﬁle (n= 4–6) (A) and representative immunoblot images and quan
biogenesis in the hippocampal extracts of 3 and 6 month old wild-type and APP/PS1 mice. pAM
GAPDH. (Statistical analysis was performed with one-way ANOVA and with Tukey's post-hoc t
student's t-test, where $ denotes p b 0.05).3.6. Mitochondrial OXPHOS expression
Deregulation in OXPHOS signaling is indicative of mitochondrial
function impairment and has been previously reported in the brains of
3 and 6 month old APPmice [46,47]. In agreementwith the abovemen-
tioned studies, we have detected a signiﬁcant reduction in OXPHOS
complexes I, II, III, and IV in the hippocampi of the 3 month old APP/
PS1 mice (Fig. 5).
3.7. Tau phosphorylation and Tau kinase levels
Since Tau expression is regulated by insulin/IGF-I, and also by AMPK,
increased Tau phosphorylation could be an early event in the brains of
APP/PS1 mice. It is well-known that Tau is a microtubule-binding pro-
tein participating in neuronal cytoskeletal dynamics maintenance and
axonal transport [55–59]. Evaluation of several Tau phosphoepitopes
by Western blotting, revealed a global increase in Tau phosphorylation
in the hippocampal extracts of APP/PS1 mice, both at 3 and 6 months
of age (Fig. 6).
3.8. Involvement of GSK-3β and CDK5 kinases in the early stages of the
amyloidogenesis and Tau phosphorylation
Insulin and IGFI signaling regulate the expression and phosphoryla-
tion of Tau proteins, as impaired insulin function leads to the over-
activation of GSK-3β, a kinase capable of Tau phosphorylation. Our
results show a signiﬁcant increase in p35 content and pCDK5 (Tyr15)/
CDK5 ratios in the hippocampus of APP/PS1 animals, compared to con-
trols, both at 3 and 6 months of age. In contrast, the protein expression
levels of GSK-3β, phosphorylated at Ser9 (inactive form), and Tyr216
(active form), as well as of IDE, remained unchanged (Fig. 7).tiﬁcation (n=4–6) (B) of themolecules related to energymetabolism andmitochondrial
PK (T172) is normalized to total AMPK levels, with the rest of the proteins normalized to
est, where * denotes p b 0.05, ** denotes p b 0.01, and *** denotes p b 0.001, and with the
Fig. 5. Representative immunoblot images and quantiﬁcation of various OXPHOS complexes, normalized to GAPDH protein levels, in the hippocampal extracts of 3 and 6 month oldwild-
type and APP/PS1 mice (n = 4–6). (Statistical analysis was performed with the student's t-test, where $ denotes p b 0.05, $$ denotes p b 0.01, and $$$ denotes p b 0.001.)
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Because Aβ oligomers induce synaptic loss in AD we evaluated pro-
tein expression levels of representative pre- and post-synaptic proteins
(synaptophysin (SYP) and PSD-95 respectively). As shown in Fig. 8,Fig. 6. Representative immunoblot images and quantiﬁcation of various Tau phosphoepitopes,
wild-type and APP/PS1 mice (n = 4–6). (Statistical analysis was performed with the student'sthere were no signiﬁcant changes in their levels in the hippocampus
of APP/PS1 mice, relative to the control tissue. Our results are in agree-
ment with a previous study by Minkeviciene et al. who did not detect
any changes in synaptic protein levels in 17 month-old APP/PS1 mice
[48].normalized to total Tau protein levels, in the hippocampal extracts of 3 and 6 month old
t-test, where $ denotes p b 0.05 and $$ denotes p b 0.01.)
Fig. 7.Representative immunoblot images andquantiﬁcation ofmolecules implicated in insulin signaling and Tauphosphorylation, in thehippocampal extracts of 3 and 6 month oldwild-
type and APP/PS1 mice (n = 4–6). pCDK (Y15), pGSK3β (Y216) and pGSK3β (S9) are normalized to their respective total unphosphorylated protein levels, whereas p35 and IDE are
normalized to GAPDH. (Statistical analysis was performed with the student's t-test, where $ denotes p b 0.05 and $$ denotes p b 0.01.)
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In the current study, we employed an integrated approach consisting
of the analyses in both the periphery and at the CNS levels, in order to
identify potential changes that occur in the early stages of the
amyloidogenic process, prior to amyloid plaque formation in a
mouse model of AD. We investigated several key metabolic routes
related to glucose uptake and insulin signaling, cellular energy
homeostasis, mitochondrial biogenesis and Tau phosphorylation.
In previous studies it was demonstrated that an increase in Aβ levels
in APP/PS1 mice is accompanied by plaque deposition in the brain andFig. 8. Representative immunoblot images and quantiﬁcation of synaptophysin and PSD-95, inmemory loss, clearly evident at the age of 6 months [11–15]. Thus,
APP/PS1 mice are commonly used in AD research [12,14,42,49]. In
agreement with these studies, we detected a signiﬁcant amyloid pep-
tide deposition and the presence of Aβ aggregates in 6 month-old
APP/PS1 mice, compared to age-matched wild-type controls. In addi-
tion, the 2 object novel object recognition test has revealed a signiﬁcant
cognitive impairment at the age of 6 months in thismodel. A novel ﬁnd-
ing in our study is the detection of the insoluble Aβ (1–42) in the brains
of 3 month old APP/PS1mice. This data is intriguing, as Aβ plaqueswere
not detectable by immunohistochemistry at such an early age. Our
results suggest that the formation of the insoluble Aβ “proto-ﬁbrils” isthe hippocampal extracts of 3 and 6 month old wild-type and APP/PS1 mice (n = 4–6).
1564 I. Pedrós et al. / Biochimica et Biophysica Acta 1842 (2014) 1556–1566an early event which leads to plaque formation by the age of 6 months.
Elevated levels of the insoluble Aβ (1–42) were previously reported in
brain homogenates of 6 month old APP/PS1 animals [50]. However,
the authors of that study did not detect any Aβ in 4 month old mice.
The discrepancy with this study could be explained by the differ-
ences in experimental methodologies. As expected, by the age of
6 months we have detected a further increase in the levels of insolu-
ble Aβ (1–42) together with the appreciable levels of both soluble
and the insoluble Aβ (1–40) as well as senile plaques,
Moreover, in the present research, we demonstrate early changes af-
fecting insulin signaling in the preplaque APP/PS1 mice. These mice
display impairment in genes involved in glucose metabolism and mito-
chondrial function, such as OXPHOS. Thus, asmentioned above, AD neu-
ropathology can be explained, in part, through alterations in glucose
metabolism. It was previously published that in 5–7 week-old APP/
PS1 mice, glucose and insulin tolerance were not impaired [16]. In our
study, we had used older animals and our results demonstrated a ten-
dency towards altered glucose tolerance already at 3 months of age,
with the 6-month-old animals exhibiting signiﬁcantly impaired glucose
and insulin tolerance. In the same model, but employing female mice,
Hiltunen et al. reported signiﬁcantly impaired glucose tolerance at
7 months of age in APP/PS1 animals, compared to wild-type controls.
Interestingly, the authors did not detect any changes in ITT, but this
could be explained by the fact that the ITT was terminated 20 min
after the insulin injection. In our study, the biggest differences in ITT be-
tween the wild-type and transgenic animals occurred between 30 and
60 min, following i.p. insulin administration. In addition, Hiltunen and
colleagues generated triple transgenic mice by cross-breeding APP/PS1
with the mice overexpressing pancreatic IGF2 [49]. While IGF2 single
mutants showed impaired glucose and insulin tolerance, in triple APP/
PS1/IGF2 animals, this phenotype was further exacerbated. In fact, our
results clearly show a signiﬁcant age-dependent increase in the IGF2
content in the hippocampus, supporting the role of IGF2 signaling in
the metabolic perturbations affecting APP/PS1 mice.
Recent studies suggest that there is a close link between insulin-
deﬁcient diabetes and cerebral amyloidosis in the pathogenesis of AD
[25,51–59]. Using a streptozotocin (STZ)-induced diabetic APP/PS1
mouse model, it has been shown that the diabetic condition promoted
the processing of APP, resulting in increased Aβ generation, neuritic
plaque formation, and spatial memory deﬁcits [24]. Patients with AD
show a remarkable deposition of Aβ peptide in the brain, whereas pa-
tients with T2DM present Islet Amyloid Polypeptide (IAPP) deposition
in pancreatic β-cells [17]. Then, AD and T2DM share common key mo-
lecular alterations in Aβ peptide processing and insulin signaling, in a
poorly understood interplay [15–17,51,52,60–65]. Chua and colleagues
have suggested that an increase in brain Aβ42 levels in 15 month-old
female APP/PS1 mice, may be dependent on impaired brain insulin
signaling [53]. However, Sadowski and colleagues demonstrated a
correlation between the hippocampal amyloid plaque levels and glu-
cose utilization at 22 months of age. It is of note, that the majority of
published studies focus on very late stages of the disease, when Aβ
plaques are fully developed [66].
Therefore, the questionwould be: Are metabolic disorders the cause
or the consequence of the AD? It is known that brain glucose metabo-
lism defects are strongly associated with memory impairment in AD
brain. Human brain imaging studies indicate that impaired glucose uti-
lization precedes the onset of cognitive deﬁcits in AD, suggesting causal-
ity [21]. In this context, the binding of insulin, IRS1 and IRS2 to the INSR,
could modulate hippocampal synaptic plasticity and memory consoli-
dation [19–22]. In agreement with this hypothesis, we detected a
small, but signiﬁcant reduction in the hippocampal Arc, Fos, Insr and
Irs2 transcripts in 3 month-old APP/PS1 mice, compared to wild-type
controls. By the age of 6 months, APP/PS1 mice develop impaired glu-
cose and insulin tolerance, accompanied by a signiﬁcant increase in
Igf2 and Igfbp2 transcripts. Interestingly, we did not detect any changes
in the transcription of Igf1, which is involved in development, cognitivefunctions and aging processes, and the alterations of which had been
linked to AD pathology.
Downstream of insulin signaling, we focused on mitochondrial
markers. Structural and functional perturbations of mitochondria in
AD have been recognized for some time, and led Swerdlow and Khan
to propose the mitochondrial cascade hypothesis [5]. This hypothesis
states that inherited mutations in mitochondrial DNA determine the
basal functional ability of mitochondria to respond to, and to recover
from stress-induced signaling. The physiopathology of AD develops
when the mitochondria lose their functional capacity, and includes
neuronal apoptosis, Aβ deposition, and neuroﬁbrillary tangles [7,
59–65]. Here, we report a signiﬁcant downregulation in mitochondrial
OXPHOS complexes in the brains of 3 month old APP/PS1 mice. Like-
wise, we detected reduced mRNA expression levels of genes related to
mitochondrial biogenesis and the regulation of energy metabolism, in-
cluding Prkaa2 subunit of AMPK, Pgc-1α, Nrf1 and Nrf2. NRF1, through
its interaction with PGC-1α, regulates mitochondrial biogenesis direct-
ly, and is a key transcriptional regulator of IDE [62–64]. The vast major-
ity of IDE protein is localized to the cytosol, with the small amounts
present in the mitochondria, where it participates in Aβ degradation.
Mitochondrial localization is dependent on the long isoform of ide
mRNA transcripts, the expression of which was found to be positively
correlated with Pgc-1α and Nrf-1 transcripts in the brains of non-
demented human patients. Interestingly, the correlation was weaker
in the brains of AD patients, suggesting an impairment of this route
[49]. The observed reduction of Pgc-1α and Nrf-1, both at the mRNA
and protein levels, in the hippocampi of young APP/PS1 animals in our
study, supports this hypothesis. The lack of changes in IDE protein levels
can be explained by the phenomenon of eclipsed distribution [63]. As
the dominant, short isoform of IDE is ubiquitously expressed in the
cytosol, any changes at the mitochondrial level would be masked by
this dominant isoform.
PGC-1α is a member of a family of transcriptional coactivators that
plays a central role in the regulation of cellular energy metabolism. It
stimulates mitochondrial biogenesis and participates in the regulation
of both carbohydrate and lipid metabolism in peripheral disorders
such as obesity and diabetes, however its role in the CNS is less clear
[55–60]. In addition to the direct effects on mitochondrial gene expres-
sion, PGC-1α is also involved in the regulation of genes that protect neu-
ronal cells from oxidative stress, such as mitochondrial superoxide
dismutase. PGC-1α is regulated by several metabolism-responsive ele-
ments like AMPK which, when activated by elevated AMP/ATP ratios,
can phosphorylate it directly [59]. Recent reports indicate that PGC-1α
could be a potential biomarker of AD disease, as reduced PGC-1α
mRNA and protein levels had been detected in AD brains [58–61]. In
agreement with this, we detected signiﬁcant reductions in PGC-1α
mRNA andprotein levels in APP/PS1 brains, compared towild-type con-
trols, at 3 and 6 months of age. We also observed a decrease in a ratio of
activated pAMPK (Thr172)/Total APMK in 3 month old APP/PS1 mice,
supporting the role of mitochondrial biogenesis impairment in the
early stages of AD. PGC-1α remains an attractive target for AD therapeu-
tic intervention [59].
AMPK is a cellular energy sensor conserved in all eukaryotic cells. It
regulates the activities of a number of key metabolic enzymes and pro-
tects cells from stresses that cause ATP depletion, by switching off ATP-
consuming biosynthetic pathways [58]. It AMPK can also phosphorylate
substrates like Tau proteins, thereby causing their hyperphosphorylation.
Tau hyperphosphorylation occurs both as a result of elevated levels of Aβ
and genetic mutations in Tau proteins, and causesmicrotubule disassem-
bly, which leads to the formation of neuroﬁbrillary tangles and synaptic
loss. In a mouse model overexpressing a P301L-mutated version of
human Tau (rTgP301L transgene), Tau hyperphosphorylation resulted
in its accumulation in the still functional dendritic spines. Signiﬁcantly,
these observations were reported in relatively young 4.5 month-old
animals, at an age when cognitive impairments were already evident,
but neither the neuronal, nor synaptic loss was detectable [61].
Fig. 9. Summary of the events, leading to the progressive amyloid plaque deposition and memory loss in an APP/PS1 mouse model of FAD.
1565I. Pedrós et al. / Biochimica et Biophysica Acta 1842 (2014) 1556–1566We detected a signiﬁcant increase in phosphorylation of several Tau
phosphoepitopes in the hippocampi of APP/PS1 mice, compared to
controls, including p-Tau (Ser199); p-Tau (Ser 205); p-Tau (Ser 396);
and p-Tau (Ser404). At the same time, the protein levels of phosphory-
lated forms of AMPK and GSK-3β remained unchanged, suggesting that
Tau phosphorylation occurs via an alternative pathway in our model.
Several studies have suggested that AD and T2DMmay share a common
pathway to pathology: the hyperactivation of CDK5 [67–69]. CDK5 acti-
vationmay cause aberrant phosphorylation of cytoskeletal components
like Tau and neuroﬁlaments. Results from our research demonstrated
an increase in p(Y15) CDK5 phosphorylation in 3 and 6 month-old
APP/PS1 mice, suggesting that CDK5 may be the kinase involved in
Tau phosphorylation [62,64–71].
In summary, our results show an early downregulation of glucose,
insulin signaling and energy metabolism pathways in an APP/PS1
mousemodel of FAD. An overview of the key events, occurring between
3 and 6 months of age in ourmodel, is presented in Fig. 9. These changes
affect the activity of key molecules involved in memory processes (Arc,
Fos) and mitochondrial regulation, such as OXPHOS, PGC-1α and NRF1,
as well as Tau phosphorylation. The data presented here reinforces the
hypothesis that the preceding events in the amyloidogenenic process
in AD are related to both insulin signaling and energy metabolism im-
pairment. Finally, we demonstrate an increase in the levels of pCDK5,
which may be responsible for Tau phosphorylation and NFT formation
in the hippocampi of the APP/PS1 mice.Acknowledgments
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